Barclays analyst Etzer Darout initiated coverage of Kymera Therapeutics (KYMR) with an Overweight rating and $60 price target Investors are rewarding oral Inflammation & Immunology assets with meaningful clinical activity, and Kymera has demonstrated encouraging early clinical data for its lead asset, KT-621, a STAT6 degrader in development for I&I indications, the analyst tells investors in a research note. Barclays is positive on Kymera heading into important proof of concept data for KT-621 in 4Q25 and sees meaningful upside potential to the stock on clinically meaningful data, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics initiated with an Overweight at Barclays
- Kymera Therapeutics initiated with an Outperform at RBC Capital
- Kymera Therapeutics Announces New Chief Legal Officer
- Kymera Therapeutics appoints Adams as Chief Legal Officer, Corporate Secretary
- Kymera Therapeutics: Promising Clinical Developments and Strategic Positioning in STAT6 Landscape Justify Buy Rating